Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by Dwizellon Dec 02, 2019 10:18am
77 Views
Post# 30412919

RE:RE:RE:RE:The new report is great, but...

RE:RE:RE:RE:The new report is great, but...
longterm56 wrote: Well, I guess you shouldn't "judge by the low volume and the price reaction" then.  Institutional investors (and wise private investors) usually don't press a button to buy millions of shares within a few hours of a news release ... especially for a small company in Canada.

I welcome the announcement ... I'd rather have it than not have any new coverage!!

   - LT



Dwizell wrote: If I judge by the low volume this morning and the price reaction, I don't think he has any kind of influence. Unfortunatly.




I agree with you for the most part of your post. I was not thinking more than a few dimes increase, but no reaction at all ?

And why the price decline sharply everytime we have a bad report if the "big guys" don't press the bottom too fast ...You think when it's good they wait to see and when it's bad the sell madly ? Strange.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities